Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190879 · ClinicalTrials.gov registry record · Phase 4
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 440
- Enrollment target
NCT00190879 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 440 participants.
The verdict
NCT00190879, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 440 participants
- Enrollment target
Study Summary
To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder
Interventions
- DRUG placebo
- DRUG Atomoxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190879
The ClinicalTrials.gov registry entry for NCT00190879 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00190879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190879 about?
NCT00190879 is a clinical study titled "Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder". To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder
What is the current status of trial NCT00190879?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 440 participants. The study started on 2005-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00190879?
The interventions under investigation include: placebo (DRUG), Atomoxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00190879?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.